Intepret these results: We found that the transcription factor TCFL5 regulates JUN levels in B cell leukemia (non BCR-ABL). TCFL5 overexpression increases JUN levels, TCFL5 knockdown decreases JUN lev

Question

Accepted Answer

> **Bottom line.** Bidirectional control of JUN levels by TCFL5 in non-BCR-ABL B-cell leukemia suggests a promoter- or RNA-mediated regulatory axis consistent with TCFL5's established E-box-driven regulation of other transcription factors, and points toward altered survival and drug-response biology.

## How should the TCFL5→JUN regulation result in non-BCR-ABL B-cell leukemia be interpreted?

Verdict: the observation is biologically plausible and mechanistically precedented in its class, but the specific TCFL5→JUN regulatory link is novel — no published study has tested TCFL5 occupancy at, or transcriptional control of, the JUN promoter. Three independent lines of evidence support the plausibility: (2) TCFL5 is active and clinically relevant in B-lineage ALL: it is overexpressed in ETV6/RUNX1-positive pre-B-ALL (fold change 2.85, qRT-PCR-validated in independent patient sets; Direct; PMID: 17956600), its activity is subtype-specific in the E/R+ leukemic regulatory network (Direct; PMID: 33218352), a preliminary study reports its expression tracking induction response and ETV6/RUNX1 status in childhood ALL (abstract only; PMID: 22897724), and its methylation/expression features sit in doxorubicin- and etoposide-response hubs across 1,231 pediatric BCP-ALL patients (Direct; PMID: 41965886). (3) JUN/AP-1 signalling is a documented proliferation, survival, and drug-response node in lymphoid malignancy — c-Jun acts as a coactivator of the B-cell fate factor PU.1 (Direct; PMID: 9988737), and AP-1-family gene expression (FOSL1, FOSB, JUNB) is positively correlated with doxorubicin survival index in BCP-ALL (Direct; PMID: 41965886).

## What agrees with your result

The strongest support for your finding is precedent for the *mechanism class*: TCFL5 is an established promoter-bound regulator of transcription-factor genes. In colorectal cancer cells, Flag-tagged TCFL5 isoforms were shown by ChIP-qPCR to bind directly to the SOX2 CORE promoter and the KLF4 promoter in regions containing bHLH E-box motifs, with luciferase reporters confirming functional transcriptional control, and reintroduction into TCFL5-knockout cells rescuing expression (Direct; PMID: 34623757). The original identification of Tcfl5 as a Clgn promoter-binding protein via a non-canonical CACGCG site in mouse spermatocytes established the same binding mode (Direct; PMID: 15585666). Your result extends this pattern to JUN, another transcription-factor gene, in a new disease context. TCFL5's relevance to B-lineage leukemia is independently well supported: it was overexpressed in ETV6/RUNX1-positive versus -negative B-ALL (fold change 2.85; one of nine validated genes able to segregate patient sets by qRT-PCR) (Direct; PMID: 17956600), single-cell and bulk profiling identified TCFL5 activity as specific to the E/R+ leukemic regulatory network (Direct; PMID: 33218352), and multi-omics integration in 1,231 pediatric BCP-ALL patients placed TCFL5 among top-ranked methylation- and expression-linked subtype-distinguishing genes, with TCFL5 CpG sites acting as hubs in methylation communities connected to doxorubicin and etoposide ex vivo response (Direct; PMID: 41965886). The downstream biology of JUN also converges with what a TCFL5→JUN axis would predict: c-Jun coactivates PU.1, a pivotal B-cell lineage transcription factor, via direct protein interaction (Direct; PMID: 9988737); and in BCP-ALL, expression of AP-1-complex genes (FOSL1, FOSB, JUNB) correlated positively with doxorubicin survival index — higher AP-1 expression marking reduced drug sensitivity — with validation of FOSB, JUNB, and ZFP36 in an independent test cohort (Direct; PMID: 41965886). An abstract further reports that TCFL5 knockdown sensitizes diffuse large B-cell lymphoma cells to doxorubicin through GPX4 regulation (abstract only; PMID: 37516394), consistent with TCFL5 supporting drug tolerance in B-cell malignancy, potentially through the AP-1 node you have now connected.

## What conflicts

No source paper in this corpus demonstrates TCFL5 binding to, or transcriptional regulation of, the JUN promoter — the specific link you report is unprecedented in the literature, so the finding stands alone until direct-binding evidence is obtained. Three published results cut against a simple pro-leukemic reading of JUN upregulation. First, JUN's effect is strongly context-dependent: elevated c-Jun activity is sufficient to trigger apoptotic cell death in fibroblasts (Direct; PMID: 9130714), c-Jun regulates both cell-cycle progression and apoptosis through distinct mechanisms (Direct; PMID: 9878062), and in vivo loss of JNK — the kinase that phosphorylates and potentiates c-Jun (Direct; PMID: 8224842; Direct; PMID: 8137421) — *increased* tumour number and growth in a Ras model, indicating the pathway can suppress rather than promote tumour development (Direct; PMID: 12629045). Second, alternative upstream inputs set JUN-family levels independently of TCFL5: JunB is a STAT3 target gene in ABC-DLBCL whose expression falls with STAT3 inactivation (Direct; PMID: 17951530). Additionally, in T-ALL patients, JUN's protein level did not significantly correlate with dexamethasone IC50 even though its downstream effector HIF1α did — a caveat on assuming JUN abundance per se predicts drug response (Direct; PMID: 38026210).

## Most likely mechanisms

A post-transcriptional route is also viable because TCFL5 is dual DNA- and RNA-binding (Direct; PMID: 34931239). The ranked mechanism list and supporting PMIDs appear in the mechanisms field; the top-ranked candidate — direct transcriptional activation of the JUN promoter — remains a hypothesis until ChIP or reporter evidence is generated in your own system.

## Caveats and alternative explanations

Several caveats temper the interpretation. (1) Cell-line dependence: TCFL5 isoform effects flipped between HCT116 and HT29 colorectal cells in a manner the authors attributed to differing basal isoform expression (Direct; PMID: 34623757). (2) Post-transcriptional ambiguity: TCFL5's eCLIP data show binding predominantly to intron regions of target mRNAs, RNase A treatment reduced TCFL5 chromatin binding, and TCFL5 interacts with RNA-processing proteins such as FXR1 and DHX9 (Direct; PMID: 34931239), so the JUN level change could reflect mRNA processing or stability rather than promoter occupancy. (3) Lineage- and genotype-specificity of the JUN literature: the tightest JUN dependence described in B-lineage leukemia is wired to BCR-ABL — Bcr-Abl activates Jun kinase and requires Jun for transformation (Direct; PMID: 8524841), and JNK inhibition synergises with dasatinib specifically in Ph+ B-ALL (Direct; PMID: 32552902) — whereas your non-BCR-ABL setting lacks this oncogenic mandate, so those papers are Indirect for your system. Evidence from T-ALL (JUN stabilises HIF1α for glucocorticoid resistance; Direct; PMID: 38026210) is likewise Indirect, being a different lineage. (4) Confounded perturbation: TCFL5 overexpression or knockdown will alter its many other targets (e.g., SOX2, KLF4 in CRC) and, in esophageal cancer models, a circRNA from the TCFL5 locus reshapes macrophage polarisation via the miR-543/FMNL2 axis (Direct; PMID: 35646112), so JUN changes could be secondary to broader transcriptional or non-coding-RNA effects. (5) Correlation is not causation at the patient level: TCFL5 features track drug-response hubs and outcomes in BCP-ALL cohorts (Direct; PMID: 41965886) and induction response in a preliminary ALL study (abstract only; PMID: 22897724), but none of these datasets connects TCFL5 to measured JUN levels in patients.

## Next experiments to settle it

The established TCFL5 experimental playbook transfers directly to the JUN question. First, test whether JUN mediates TCFL5's phenotypes: re-express JUN in TCFL5-knockdown cells and measure proliferation, apoptosis, and drug sensitivity (doxorubicin, glucocorticoid), with PTEN/AKT signalling as a survival readout — c-Jun is known to promote survival by suppressing PTEN (Direct; PMID: 16676006), and AP-1 expression tracks doxorubicin response in BCP-ALL (Direct; PMID: 16676006), giving concrete expected directions. Second, resolve the transcriptional-versus-post-transcriptional question: run a time-course comparing nascent JUN transcription (e.g., RT-qPCR of pre-mRNA or nascent RNA) against JUN protein levels with cycloheximide/proteasome treatment, and perform TCFL5 eCLIP or RNA-IP to ask whether TCFL5 binds JUN pre-mRNA introns — necessary because TCFL5's dual DNA/RNA-binding activity means promoter-based regulation cannot be assumed (Direct; PMID: 34931239).

## Landscape check

The literature landscape maps how the gathered papers connect through shared genes, chemicals, diseases and processes, reported mechanisms, and citations. These notes compare the brief with that map.

**Sources that disagree**
- "First, JUN's effect is strongly context-dependent: elevated c-Jun activity is sufficient to trigger apoptotic cell death in fibroblasts, c-Jun regulates both cell-cycle progression and apoptosis through distinct mechanisms, and in vivo loss of JNK — the kinase that phosphorylates and potentiates c-Jun — *increased* tumour number and growth in a Ras model, indicating the pathway can suppress rather than promote tumour development" cites *Induction of apoptosis by the transcription factor c‐Jun* (1997) and *c‐Jun regulates cell cycle progression and apoptosis by distinct mechanisms* (1999), which report opposite results: the citation check found that one contradicts the claim the other supports: While the title-level statement is supported, the paper reports c-Jun is required for G1 progression and protects cells from apoptosis, which contradicts rather than supports the qualifier that c-Jun can promote cell-cycle arrest and apoptosis depending on context.

**Central papers not cited**
- *Human Proto-Oncogene c- jun Encodes a DNA Binding Protein with Structural and Functional Properties of Transcription Factor AP-1* (1987): linked to 30 other papers in this set through Neoplasms, Jun.
- *Cellular Transformation and Malignancy Induced by ras Require c-jun* (1996): linked to 30 other papers in this set through Neoplasms, Jun, FOS.
- *The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation* (1991): linked to 21 other papers in this set through FOS.
- *Survival signaling mediated by c-Jun NH2-terminal kinase in transformed B lymphoblasts* (2002): linked to 30 other papers in this set through Neoplasms, Jun, MAPK8.

### Research notebook

**What is known about TCFL5 (transcription factor-like 5): molecular function, domains, and reported roles in cancer including hematologic malignancies?**

TCFL5 is recurrently dysregulated in cancer: it is upregulated in leukaemia and seminoma, lies in the 20q amplicon driving colorectal tumour progression, and its complete deletion in colorectal cancer cells reduces proliferation and in vivo tumour growth (with loss of viability in some lines), while in diffuse large B-cell lymphoma TCFL5 knockdown sensitises cells to doxorubicin via GPX4 regulation. In pediatric BCP-ALL, TCFL5 is a subtype-distinguishing gene whose methylation and expression features are linked to doxorubicin/etoposide response.

_Status: verified • Confidence: high_

- The TCFL5 locus encodes four transcripts, including canonical TCFL5_E8 and the shorter CHA isoform, all sharing the bHLH domain; TCFL5 was first described in spermatocytes and CHA was previously described as a USF1 partner in leukaemic T lymphocytes where it inhibits CD2 expression. (PMID 34623757, introduction)
  - TCFL5 is reported as upregulated in leukaemia and seminomas, and in colorectal cancer is higher in carcinomas than adenomas (predominantly by increased mRNA rather than 20q amplification); complete CRISPR knockout of the TCFL5 locus reduced proliferation, spheroid formation and in vivo tumour growth, and knockout was not viable in HT29 and SW620 cells, indicating a role in survival. (PMID 34623757, results)
  - In an integrative multi-omics map of 1231 pediatric BCP-ALL patients, TCFL5 was among the top-ranked methylation- and expression-linked genes distinguishing BCP-ALL subtypes and B-cell development states; TCFL5 methylation at hub CpG sites was associated with ex vivo response to etoposide and doxorubicin. (PMID 41965886, results)

---

**What is the relationship between TCFL5 and JUN/AP-1 signaling in published literature — is there prior evidence of TCFL5 controlling JUN expression?**

Published literature contains no direct demonstration that TCFL5 binds or controls the JUN promoter — the TCFL5→JUN link appears to be novel. However, two lines of prior evidence make the finding biologically plausible: TCFL5 is documented to directly bind E-box-containing promoters of transcription-factor genes (CLGN, SOX2, KLF4) via its bHLH domain, and TCFL5 features are intertwined with AP-1-family gene expression and drug response in B-cell precursor ALL molecular maps.

_Status: verified • Confidence: medium_

- TCFL5 isoforms directly bind the SOX2 and KLF4 promoters (ChIP-qPCR) at regions containing bHLH E-box motifs, and regulate their transcription as shown by promoter luciferase reporter assays — a direct precedent for TCFL5 controlling transcription-factor gene expression, though no prior study tested the JUN promoter. (PMID 34623757, results)
  - Tcfl5 directly interacts with the Calmegin gene promoter in spermatogenesis, the original demonstration that TCFL5 binds gene promoters as a sequence-specific bHLH factor. (PMID 15585666, abstract)
  - In the pediatric BCP-ALL multi-omics map, TCFL5 is a subtype-distinguishing gene within the same cross-modal element (CME 2) framework in which AP-1 complex genes (FOSL1, FOSB, JUNB) were linked to topoisomerase-inhibitor response, co-localising TCFL5 and AP-1 biology in B-ALL without demonstrating a direct regulatory relationship. (PMID 41965886, discussion)

---

**What roles do JUN and AP-1 play in B-cell biology and B-cell leukemia/lymphoma pathogenesis (proliferation, survival, apoptosis)?**

JUN (c-Jun) and AP-1 play context-dependent but well-documented roles in B-cell malignancy: c-Jun and JunB are aberrantly expressed in Hodgkin lymphoma where they stimulate proliferation and synergise with NF-κB; c-Jun promotes survival by suppressing PTEN; JNK-mediated c-Jun signalling supports survival of transformed B lymphoblasts; and c-Jun co-activates the B-cell fate factor PU.1 — while in other contexts c-Jun induces cell-cycle arrest and apoptosis.

_Status: verified • Confidence: medium_

- Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells and stimulate proliferation, synergising with NF-κB. (PMID 12145210, abstract)
  - c-Jun promotes cellular survival by suppression of PTEN, showing a pro-survival function of c-Jun in transformed cells. (PMID 16676006, abstract)
  - c-Jun NH2-terminal kinase-mediated signalling provides survival signalling in transformed B lymphoblasts, indicating JNK/JUN-axis dependence in B-lineage transformed cells. (PMID 12161751, abstract)
  - c-Jun acts as a JNK-independent coactivator of the PU.1 transcription factor, linking JUN directly to B-cell transcriptional circuitries. (PMID 9988737, abstract)
  - c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms — c-Jun can also promote cell-cycle arrest and apoptosis depending on context, so the direction of JUN's effect is cell-type and state dependent. (PMID 9878062, abstract)
  - The transcription factor c-Jun can induce apoptosis in certain contexts, underscoring that JUN level changes may have opposite phenotypic outcomes in different cellular backgrounds. (PMID 9130714, abstract)

---

**What is the biological significance of JUN regulation in non-BCR-ABL (Ph-negative) B-cell leukemia specifically, and does JUN dependence differ from Ph+ disease?**

In Ph+ disease, JUN is wired into the BCR-ABL oncogenic circuitry — BCR-ABL activates Jun kinase and requires Jun for transformation, and JNK inhibition cooperates with dasatinib in BCR-ABL-positive B-ALL. In Ph-negative B-ALL, no oncogenic kinase mandate for JUN is established, but AP-1-family gene expression tracks chemotherapy response and JUN knockdown drives glucocorticoid resistance in T-ALL, so JUN level changes in non-BCR-ABL B-cell leukemia plausibly modulate survival and drug sensitivity rather than being transformation-required.

_Status: verified • Confidence: medium_

- The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation — in Ph+ leukemia, JUN is a downstream effector of the driving oncogene. (PMID 8524841, abstract)
  - Combination therapy with the tyrosine kinase inhibitor dasatinib and c-Jun N-terminal kinase inhibition is effective against BCR-ABL-positive B-cell acute lymphoblastic leukemia, showing AP-1/JNK dependence in Ph+ B-ALL. (PMID 32552902, abstract)
  - JUN mediates glucocorticoid resistance by stabilizing HIF1α in T-cell acute lymphoblastic leukemia — direct evidence that JUN levels determine drug response in lymphoid leukemia outside the BCR-ABL context. (PMID 38026210, abstract)
  - In pediatric BCP-ALL (both Ph+ and Ph-negative subtypes included), expression of AP-1 complex genes (FOSL1, FOSB, JUNB) was positively correlated with ex vivo doxorubicin response, i.e., high AP-1 expression marked reduced sensitivity to topoisomerase inhibitors, across molecular subtypes. (PMID 41965886, discussion)

---

**What downstream consequences of JUN modulation (target genes, survival pathways, drug sensitivity) would be expected if TCFL5-JUN regulation is functional in these cells?**

If the TCFL5→JUN regulation is functional, expected downstream consequences follow published JUN/AP-1 biology: altered survival signalling (PTEN suppression), altered chemotherapy response (glucocorticoid resistance via HIF1α stabilisation in T-ALL; doxorubicin sensitivity tracking AP-1 gene expression in BCP-ALL; TCFL5 knockdown sensitising DLBCL to doxorubicin via GPX4/ferroptosis), and altered immune phenotype (AP-1-driven PD-L1 induction in EBV-associated lymphomas).

_Status: verified • Confidence: medium_

- c-Jun promotes cellular survival by suppression of PTEN — JUN upregulation would be expected to attenuate PTEN/PI3K-axis restraint and support survival. (PMID 16676006, abstract)
  - JUN stabilises HIF1α and thereby mediates glucocorticoid resistance in T-ALL; if TCFL5 raises JUN levels in B-ALL, reduced glucocorticoid sensitivity would be a testable consequence. (PMID 38026210, abstract)
  - AP-1 complex genes (FOSL1, FOSB, JUNB) in BCP-ALL patients were positively correlated with survival index after doxorubicin (i.e., higher AP-1 expression = lower drug sensitivity), and this association was validated in an independent test cohort for FOSB, JUNB and ZFP36. (PMID 41965886, results)
  - TCFL5 knockdown sensitises DLBCL to doxorubicin via regulation of GPX4 — consistent with a TCFL5→JUN→drug-tolerance axis in a B-cell lymphoma setting. (PMID 37516394, abstract)
  - Constitutive AP-1 activity, together with EBV infection, induces PD-L1 in Hodgkin lymphomas and post-transplant lymphoproliferative disorders, implying that JUN modulation can change the immune-evasion phenotype of lymphoid malignancies. (PMID 22271878, abstract)

---

**What follow-up experiments would distinguish direct transcriptional regulation of JUN by TCFL5 from indirect effects (e.g., chromatin binding assays, promoter reporters, protein stability, TIMELESS/interactions)?**

To distinguish direct transcriptional regulation of JUN by TCFL5 from indirect effects, the established TCFL5 playbook is directly transferable: ChIP-qPCR/ChIP-seq for TCFL5 occupancy at the JUN promoter, JUN promoter-luciferase reporters (including E-box mutant constructs), CRISPR rescue with promoter-binding-defective TCFL5, and time-course nascent-transcription assays to separate transcriptional from protein-stability effects. RT-qPCR versus Western readouts after cycloheximide/proteasome inhibition would test whether TCFL5 affects JUN protein turnover, and rescue experiments restoring JUN after TCFL5 knockdown would test whether JUN mediates TCFL5's phenotypic effects.

_Status: verified • Confidence: medium_

- The precedent experiment suite for TCFL5 — Flag-tagged TCFL5 ChIP-qPCR on gene promoters, promoter-region luciferase reporter assays, E-box-motif analysis, and reintroduction into TCFL5-knockout cells — directly established TCFL5 as a promoter-bound regulator of transcription-factor genes (SOX2, KLF4) and is directly transferable to testing the JUN promoter. (PMID 34623757, methods)
  - Tcfl5's ability to bind a defined gene promoter (Calmegin) was demonstrated by direct promoter interaction assays in spermatogenesis cells, establishing the methodological basis for testing TCFL5 occupancy at the JUN promoter. (PMID 15585666, abstract)
  - TCFL5 is a potential DNA- and RNA-binding protein essential for male fertility, implying TCFL5 could also act through non-promoter DNA elements or RNA-binding mechanisms — a reason the protein-stability/RNA-level arm of the follow-up experiments is necessary rather than assuming purely promoter-mediated regulation. (PMID 34931239, abstract)
  - c-Jun level changes have measurable downstream survival consequences (PTEN suppression), providing a functional readout (PTEN/PI3K signalling, apoptosis) for JUN-rescue experiments after TCFL5 perturbation. (PMID 16676006, abstract)

Intepret these results: We found that the transcription factor TCFL5 regulates JUN levels in B cell leukemia (non BCR-ABL). TCFL5 overexpression increases JUN levels, TCFL5 knockdown decreases JUN lev

How should the TCFL5→JUN regulation result in non-BCR-ABL B-cell leukemia be interpreted?

What agrees with your result

What conflicts

Most likely mechanisms

Caveats and alternative explanations

Next experiments to settle it

Landscape check

Research notebook

What has been published since 18/09/2026 that confirms or contradicts this result?

What agrees with your result

What conflicts

Most likely mechanisms

Caveats and alternative explanations

Next experiments to settle it

Landscape check

Research notebook

What has been published since 18/09/2026 that confirms or contradicts this result?

What agrees with your result

What conflicts

Most likely mechanisms

Caveats and alternative explanations

Next experiments to settle it

Landscape check

Research notebook

Top cited papers